28 results were returned
We were successful in defending our clients in a major Supplementary Protection Certificate (SPC) case.
We have advised Aphria Deutschland GmbH on its tender for the cultivation, processing and delivery of cannabis for medical purposes.
International law firm Bird & Bird has advised Chiesi Farmaceutici S.p.A. ("Chiesi") on the in-licence of Raxone® -- an orphan drug used in the treatment of Leber's hereditary optic neuropathy ("LHON")
The Dutch competition authority, ACM, initiated a market study in 2018 into the effect of the introduction of biosimilars on the competition between TNF alfa inhibitors. TNF-alfa inhibitors are biological medicines that ...
Sanofi sought a compulsory licence for the distribution of its high cholesterol drug Praluent® but this was dismissed in preliminary proceedings (docket no: 3 LiQ 1/18).
On September 26, 2019, the Higher Regional Court of Düsseldorf confirmed on appeal that Teva Pharmaceutical Industries Ltd. (“Teva”) – one of Bird & Bird’s key clients – is entitled to a preliminary injunction against ...
The Bill of the Law on the organization and transformation of the French healthcare system at the French parliament, adoption of the final version is expected for the end of July.
This new regime, applicable either to types of intangible assets or to a family of products or services, provides taxation at a reduced rate of 10% of net income generated by industrial property including patents and ...
Telemedicine is governed by Article L6316-1 and R6316-1 and seq of the French public health code (code de la santé publique (CSP)).
Before the entry into force of the GDPR on May 25th 2018, healthcare professionals and facilities and professionals in medico-social sectors empowered by law in France had to comply with the provisions stated in the ...